These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22137633)

  • 21. Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement.
    van Lingen RG; van Erp PE; Seyger MM; de Jong EM; de Boer-van Huizen RT; Driessen RJ; van de Kerkhof PC
    Acta Derm Venereol; 2009; 89(5):518-20. PubMed ID: 19734982
    [No Abstract]   [Full Text] [Related]  

  • 22. Infliximab monotherapy in psoriasis: a case of rapid clinical and histological response.
    Vincek V; Jacob SE; Nassiri M; Herbert LM; Nadji M; Kerdel FA
    Int J Dermatol; 2004 Apr; 43(4):303-8. PubMed ID: 15090021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
    Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
    Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [What are the objectives of moderate to severe psoriasis treatment?].
    Ortonne JP
    Ann Dermatol Venereol; 2008 Jul; 135 Suppl 5():S281-4. PubMed ID: 18721665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
    Puig L
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three years' experience with infliximab in recalcitrant psoriasis.
    Ahmad K; Rogers S
    Clin Exp Dermatol; 2006 Sep; 31(5):630-3. PubMed ID: 16901301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab rescue of efalizumab withdrawal flare and psoriasis-precipitated depression.
    Yip L; Harrison S; Foley P
    Australas J Dermatol; 2008 Nov; 49(4):250-1. PubMed ID: 18855796
    [No Abstract]   [Full Text] [Related]  

  • 30. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
    Kamili QU; Miner A; Hapa A; Menter A
    J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lentigines in previous psoriatic plaques in a patient treated with infliximab.
    Bardazzi F; Magnano M; Antonucci VA; Balestri R; Sgubbi P; Patrizi A
    Eur J Dermatol; 2012; 22(5):698-9. PubMed ID: 22940696
    [No Abstract]   [Full Text] [Related]  

  • 32. Successful treatment of hand and foot psoriasis with infliximab.
    Di Lernia V; Guareschi E
    Dermatol Online J; 2010 Jul; 16(7):8. PubMed ID: 20673536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H; Nakagawa H;
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience with infliximab biosimilar in psoriasis.
    Ricceri F; Pescitelli L; Lazzeri L; Prignano F
    Br J Dermatol; 2017 Dec; 177(6):e347-e348. PubMed ID: 28646577
    [No Abstract]   [Full Text] [Related]  

  • 35. Misunderstandings.
    Feldman SR
    J Dermatolog Treat; 2007; 18(1):4. PubMed ID: 17365258
    [No Abstract]   [Full Text] [Related]  

  • 36. Infliximab for the treatment of severe pustular psoriasis.
    Elewski BE
    J Am Acad Dermatol; 2002 Nov; 47(5):796-7. PubMed ID: 12399781
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of severe refractory psoriasis with infliximab. Clinical outcomes after one year of therapy].
    Mahiques Santos L; Martínez Menchón T; Sánchez Carazo JL; Fortea Baixauli JM
    Med Clin (Barc); 2005 Jun; 125(4):159. PubMed ID: 15989862
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study.
    Bissonnette R; Poulin Y; Guenther L; Lynde CW; Bolduc C; Nigen S
    J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1402-8. PubMed ID: 21349113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosing latent tuberculosis infection in patients with psoriasis under antitumour necrosis factor-α treatment: every new solution breeds new doubts.
    Sánchez-Moya AI; Daudén E
    Br J Dermatol; 2011 Jan; 164(1):208-9. PubMed ID: 21054332
    [No Abstract]   [Full Text] [Related]  

  • 40. Infliximab and nephrotic syndrome.
    Chin G; Luxton G; Harvey JM
    Nephrol Dial Transplant; 2005 Dec; 20(12):2824-6. PubMed ID: 16204273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.